References
- Broome J D. Evidence that the l-asparaginase of guinea pig serum is responsible for its antilymphoma effects and properties of the l-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. J Exp Med 1963; 118: 99–120
- Müller H J, Boos J. Use of l-asparaginase in childhood ALL. Critical Rev Oncol Hematol 1998; 28: 97–113
- Eden O B, Shaw M P, Lilleyman J S, Richard S. Non-randomized study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukemia. Med Ped Oncol 1990; 18: 497–502
- Nesbit M, Chard R, Evans A. Evaluation of intramuscular versus intravenous administration of l-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979; 1: 120–124
- Cheung N K, Chau I Y, Coccia P F. Antibody response to Escherichia coliL-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986; 19: 400–408
- Asselin B L, Whitin J C, Coppola D J, Rupp I P, Sallan S E, Cohen H J. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780–1786
- Zalewska-Szewczyk B, Andrzejewski W, Bodalski J. Development of anti-asparaginase antibodies in childhood lymphoblastic leukemia. Pediatric Blood Cancer 2004; 43: 600–602
- Panosyan E H, Seibel N L, Martin-Aragon S, Gaynon P S, Avramis I A, Sather H, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2004; 26: 217–226
- Wahn V, Fabry U, Korholz D, Reinhardt D, Jurgens H, Gobel U. Modified pharmacokinetics of l-asparaginase from E. coli by formation of specific antibodies to l-asparaginase of different immunoglobulin classes in children with acute lymphoblastic leukemia. Pediatr Pharmacol 1983; 3: 303–311
- Woo M H, Hak L J, Storm M C, Evans W E, Sandlund J T, Rivera G K. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 1998; 12: 1527–1533
- Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig W D, Henze G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 – 1995. Berlin-Frankfurt-Munster. Leukemia 2000; 14: 2205–2222
- Müller H J, Löning L, Horn A, Schwabe D, Gunkel M, Schrappe M, et al. Pegylated asparaginase (Oncaspar™) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 2000; 110: 379–384
- Killander D, Dohlwitz A, Engstedt L. Hypersensitive reactions and antibody formation during l-asparaginase treatment of children and adults with acute leukemia. Cancer 1976; 37: 220–228
- Woo M H, Hak L J, Storm M C, Sandlund J T, Ribeiro R C, Rivera G K, et al. Hypersensivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1525–1532
- Larson R A, Fretzin M H, Dodge R K, Schiffer C A. Hypersensitivity reactions to l-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998; 12: 660–665
- Albertsen B K, Schrøder H, Jakobsen P, Avramis V I. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002; 38: 310–316
- Klug-Albertsen B, Schmiegelow K, Schroder H, Carlsen N T, Rosthoy S, Avramis V I, et al. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study. Cancer Chemother Pharmacol 2002; 50: 117–120